Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04659707 · ClinicalTrials.gov registry record · Phase 1
Hyperpolarized 129Xe MRI of Survivors of COVID-19
A Phase 1 study of Covid19, sponsored by University of Kansas Medical Center.
- Active
- Registry status
- Phase 1
- Development phase
- 20
- Enrollment target
- 1
- Study location
NCT04659707 is a Phase 1 study of Covid19 that is active but no longer recruiting, run by University of Kansas Medical Center. The registered enrollment target is 20 participants, below the 2,702-participant average among 94 other Covid19 trials with a reported enrollment target (99% lower). The trial reports 1 study location across 1 state.
The verdict
NCT04659707, a Phase 1 study of Covid19, is active but no longer recruiting, sponsored by University of Kansas Medical Center.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 20 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to evaluate pulmonary function of patients recovering from mild, moderate, and severe COVID-19 disease using hyperpolarized 129Xe MRI.
Conditions Studied
Interventions
- DRUG Hyperpolarized Xe129
Study Locations (1)
Kansas
- University of Kansas Medical Center - Kansas City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2021-02-22 |
| Est. Completion | 2025-05-01 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04659707
The ClinicalTrials.gov registry entry for NCT04659707 describes a study currently listed as active not recruiting, categorized as Phase 1. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 2,702-participant average among 94 other Covid19 trials with a reported enrollment target (99% lower). The listed sponsor is University of Kansas Medical Center, which has 408 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Covid19 appearing as the primary indexed condition, and to 1 intervention - of which Hyperpolarized Xe129 is the first listed.
NCT04659707 reports 1 study location spanning 1 distinct geographic area - top geographies include Kansas.
Frequently Asked Questions
What is clinical trial NCT04659707 about?
NCT04659707 is a clinical study titled "Hyperpolarized 129Xe MRI of Survivors of COVID-19". The purpose of this study is to evaluate pulmonary function of patients recovering from mild, moderate, and severe COVID-19 disease using hyperpolarized 129Xe MRI.
What is the current status of trial NCT04659707?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 20 participants. The study started on 2021-02-22. Estimated completion is 2025-05-01.
What conditions does trial NCT04659707 study?
This clinical trial studies the following conditions: Covid19.
What interventions are being tested in trial NCT04659707?
The interventions under investigation include: Hyperpolarized Xe129 (DRUG).
Who is sponsoring clinical trial NCT04659707?
This trial is sponsored by University of Kansas Medical Center, which has 408 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04659707 being conducted?
This trial has 1 study location across Kansas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Covid19
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Exercise Therapy in Cancer Patients Who Are Recovering From COVID-19
COMPLETED · Phase 1
-
RCT of Modified Qing Fei Pai Du Tang (mQFPD) for COVID-19
COMPLETED · Phase 1
-
Transfer of Infection Fighting Immune Cells Generated in the Laboratory to High Risk Patients With COVID-19 Infection
COMPLETED · Phase 1
-
COVID-19 Study of Safety and Tolerability of Alvelestat
COMPLETED · Phase 1
-
Safety and Immunogenicity Trial of an Oral SARS-CoV-2 Vaccine (VXA-CoV2-1) for Prevention of COVID-19 in Healthy Adults and Boost (VXA-CoV2-1.1-S) at 1 Year Post Initial Vaccination in Subset of Subjects
COMPLETED · Phase 1
-
Electrical Stimulation for Critically Ill Covid-19 Patients
COMPLETED · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.